Contemporary Endocrinology

Volume 2

Contemporary Endocrinology

(formerly *The Year in Endocrinology*)

Editor-in-Chief: SIDNEY H. INGBAR • Boston, Massachusetts

Editorial Board

EDWARD G. BIGLIERI • San Francisco, California
LEWIS E. BRAVERMAN • Worcester, Massachusetts
WILLIAM H. DAUGHADAY • St. Louis, Missouri
DANIEL D. FEDERMAN • Boston, Massachusetts
CHARLES R. KLEEMAN • Los Angeles, California
DOROTHY T. KRIEGER • New York, New York
MORTIMER B. LIPSETT • Bethesda, Maryland
ROBERT L. NEY • Chapel Hill, North Carolina
GARY L. ROBERTSON • Indianapolis, Indiana
GRIFF T. ROSS • Bethesda, Maryland
LOUIS M. SHERWOOD • Chicago, Illinois
KENNETH A. WOEBER • San Francisco, California

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.

Contemporary Endocrinology

Volume 2

Edited by

Sidney H. Ingbar, M.D.

William B. Cattle Professor of Medicine

Harvard Medical School

Director, Thorndike Laboratory of Harvard Medical School

at the Beth Israel Hospital

Boston, Massachusetts

**PLENUM MEDICAL BOOK COMPANY
NEW YORK AND LONDON**

The Library of Congress has cataloged this serial title as follows:

Contemporary endocrinology. v. 1- 1979-

New York, Plenum Medical Book Co.

v. ill. 24 cm.

Annual.

Editor: 1979- S. H. Ingbar.

Supersedes: Year in endocrinology, ISSN 0146-4078.

Key title: Contemporary endocrinology, ISSN 0196-8653.

1. Endocrinology—Periodicals. I. Ingbar, Sidney H.

[DNLM: W1 CO769MPE]

QP187.A1Y4

612'.4'005

80-640369

MARC-S

Library of Congress

[8404r84]rev

ISBN-13: 978-1-4684-4819-1 e-ISBN-13: 978-1-4684-4817-7

DOI: 10.1007/978-1-4684-4817-7

©1985 Plenum Publishing Corporation

Softcover reprint of the hardcover 1st edition 1985

233 Spring Street, New York, N.Y. 10013

Plenum Medical Book Company is an imprint of Plenum Publishing Corporation

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Contributors

Edward G. Biglieri, M.D. • Chief, Endocrinology Service of the Medical Services and Director of the Clinical Study Center, San Francisco General Hospital Medical Center; Professor of Medicine, Department of Medicine, University of California School of Medicine, San Francisco, California 94120

Lewis E. Braverman, M.D. • Professor of Medicine; University of Massachusetts Medical School, Worcester, Massachusetts 01605

William H. Daughaday, M.D. • Professor of Medicine; Director, Metabolism Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

Daniel D. Federman, M.D. • Professor of Medicine, Harvard Medical School, Boston, Massachusetts 02115

Charles R. Kleeman, M.D. • Professor of Medicine, Chief Emeritus, Division of Nephrology, Department of Medicine, UCLA Center for the Health Sciences and School of Medicine, Los Angeles, California 90024

Karen E. Kleeman, M.D. • Department of Psychiatry and Biobehavioral Science, UCLA Neuropsychiatric Institute and School of Medicine, Los Angeles, California 90024

Dorothy T. Krieger, M.D. • Professor of Medicine, Director, Division of Endocrinology, Mount Sinai Medical Center, New York, New York 10029

- L. Landsberg, M.D.** • Departments of Medicine, Beth Israel Hospital, Charles A. Dana Research Institute, and Thorndike Laboratories, Harvard Medical School, Boston, Massachusetts 02115
- Gary R. Robertson, M.D.** • University of Chicago School of Medicine, Chicago, Illinois 60637
- Louis M. Sherwood, M.D.** • Baumritter Professor and Chairman, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461
- Kenneth A. Woeber, M.D.** • Chief of Medicine, Department of Medicine, Mt. Zion Hospital and Medical Center; Professor of Medicine, University of California School of Medicine, San Francisco, California 94120
- J. B. Young, M.D.** • Departments of Medicine, Beth Israel Hospital, Charles A. Dana Research Institute, and Thorndike Laboratories, Harvard Medical School, Boston, Massachusetts 02115

Contents

Chapter 1

Neuroendocrinology

Dorothy T. Krieger

1.1. Introduction	1
1.2. Biosynthesis of CNS Peptides	2
1.2.1. ACTH and Related Peptides in Brain	2
1.2.2. Vasopressin, Oxytocin, and Neurophysins	3
1.2.3. Somatostatin	3
1.3. Extrahypothalamic Localization of "Hypothalamic Releasing Factors" and Peptides	4
1.3.1. ACTH	4
1.3.2. Vasopressin	5
1.3.3. Somatostatin	5
1.3.4. Gonadotropin-Releasing Hormone (LHRH)	7
1.3.5. Thyrotropin-Releasing Hormone	7
1.4. Possible Functional Homeostatic Significance of Brain Peptides	8
1.4.1. Cognitive Behavior	8
1.4.2. Effects on Feeding	8
1.5. Possible Functions of Opioid-like Peptides	9
1.5.1. On Prolactin Release	9
1.5.2. In Clinical Syndromes	11
1.6. Results of Transsphenoidal Hypophysectomy for Hyperfunctioning Pituitary Adenomas	12
1.6.1. Acromegaly	13

1.6.2. Prolactinomas	17
1.6.3. Cushing's Disease	18
References	18

Chapter 2

Prolactin and Growth Hormone in Health and Disease

William H. Daughaday

2.1. Introduction	27
2.2. Prolactin	28
2.2.1. The Prolactin Gene and mRNA	28
2.2.2. Prolactin Molecular Heterogeneity	28
2.2.3. Amniotic Fluid Prolactin	29
2.2.4. Pituitary Prolactin Secretion in Pregnancy	30
2.2.5. Physiologic Secretion of Prolactin and Functional Abnormalities	31
2.2.6. Hyperprolactinemia in Uremia	33
2.2.7. Prolactin Effects on Androgens	33
2.2.8. Effects of Pharmacologic Agents on Prolactin Secretion	35
2.2.9. Provocative Tests of Prolactin Secretion	36
2.2.10. Etiology of Prolactinomas	37
2.2.11. Hypothalamic Function Associated with Prolactinoma	38
2.2.12. Clinical Manifestations of Prolactinomas	39
2.2.13. Diagnosis of Prolactinomas	40
2.2.14. Pituitary Function in Patients with Prolactinoma	42
2.2.15. Treatment with Dopaminergic Agents	42
2.2.16. Neurosurgical Treatment	46
2.3. GH	46
2.3.1. GH Genes and mRNA	46
2.3.2. GH Heterogeneity	47
2.3.3. Homologous Radioreceptor Assays for hGH	48
2.3.4. GH Regulation by Somatostatin	48
2.3.5. GH Regulation by Somatocrinin (GHRH)	49
2.3.6. GH Regulation in Men	50
2.3.7. GH Effects on Calcium and Phosphorus Metabolism	51
2.3.8. Pituitary Pathology in Acromegaly	53
2.3.9. Control of GH Secretion in Acromegaly	54
2.3.10. Disturbed Organ Physiology in Acromegaly	55
2.3.11. Diabetes and Acromegaly	57
2.3.12. Treatment of Acromegaly	58

2.4. Hypopituitarism	60
2.4.1. Etiology	60
2.4.2. Familial Isolated GH Deficiency	62
2.4.3. Hormonal Studies in Hypopituitary Children	62
2.4.4. GH Treatment	64
2.4.4.1. GH Refractoriness	65
2.5. Somatomedins	65
2.5.1. Structure	65
2.5.2. Measurement of Somatomedins	66
2.5.3. Somatomedin-Binding Proteins of Serum	67
2.5.4. Variation in Normal Serum Somatomedin Levels	68
2.5.5. Somatomedin Levels in Malnutrition and Uncontrolled Diabetes Mellitus	69
2.5.6. Somatomedins in Chronic Renal Failure	70
2.5.7. Somatomedin Levels in Hypopituitarism	71
References	72

Chapter 3

The Thyroid

Kenneth A. Woeber and Lewis E. Braverman

3.1. Hypothalamic–Pituitary–Thyroid Interrelationships	87
3.2. Thyroid Hormone and Thyroglobulin Synthesis and Release	91
3.3. Peripheral Metabolism, Action, and Serum Protein Binding of the Thyroid Hormones	94
3.4. Fetal and Neonatal Thyroid Function	105
3.5. Hyperthyroidism	107
3.6. Hypothyroidism	119
3.7. Nontoxic Goiter	123
3.8. Thyroid Carcinoma	125
3.9. Miscellaneous	128
References	128

Chapter 4

The Testis

Daniel D. Federman

4.1. Introduction	157
4.2. Intrauterine and Neonatal Function	157

4.2.1. Embryonic Sex Differentiation	157
4.2.1.1. Normal Controls	157
4.2.1.2. Defects in Fetal Sex Differentiation	159
4.2.2. Testicular Function in Childhood	162
4.3. Puberty	163
4.4. Adult Physiology	167
4.4.1. The Hypothalamus and Pituitary	167
4.4.2. The Testis	170
4.4.2.1. Steroidogenesis	170
4.4.2.2. Spermatogenesis	172
4.4.2.3. Effect of Age	172
4.5. Adult Pathophysiology	173
4.5.1. Gonadotropin Deficiencies	173
4.5.2. The Testis	178
4.5.2.1. Steroidogenesis	178
4.5.2.2. Tubular Defects	179
4.6. Effect of Systemic Disease on Gonadal Function	183
4.7. Testicular Tumors	185
4.8. Miscellaneous	186
4.8.1. Gynecomastia	186
4.8.2. Impotence	187
References	188

Chapter 5

Aldosterone and Renin

Edward G. Biglieri

5.1. A Reexamination and Further Definition of Congenital Adrenal Hyperplasia through the Examination of Steroids in the Mineralocorticoid Hormone Pathways	203
5.1.1. 21-Hydroxylase Deficiency [Simple Virilizing (SV), Nonsalt-Losing, and Salt-Losing (SL) Types]	204
5.1.2. 11 β -Hydroxylase Deficiency	206
5.1.3. 17 α -Hydroxylase Deficiency	207
5.2. The Hypokalemic and Hypertensive Syndromes with Suppressed Renin and Aldosterone Production	207
5.2.1. Defect in Terminal (or Peripheral) Steroid Metabolism	208
5.2.2. Glucocorticoid Insensitivity	209
5.3. Primary Hyperaldosteronism	210
5.3.1. Primary Aldosteronism	210
5.3.2. Idiopathic Hyperaldosteronism (IHA, Adrenal Hyperplasia)	211

5.3.3. Glucocorticoid-Remediable Hyperaldosteronism (GRHA)	212
References	213

Chapter 6

Sympathoadrenal System

L. Landsberg and J. B. Young

6.1. Introduction	217
6.2. Sympathetic Responses during Cold Exposure: Regulation of Nonshivering Thermogenesis	218
6.2.1. Role of the Sympathetic Nervous System in Temperature Maintenance during Cold Exposure	218
6.2.2. Sympathetic Activation in the Cold	218
6.2.2.1. Adrenal Medulla	219
6.2.2.2. Central Regulation	219
6.2.3. Components of the Sympathetic Response	219
6.2.4. Nonshivering Thermogenesis	220
6.2.4.1. "Adaptive" or "Regulatory" Thermogenesis	220
6.2.4.2. Thermogenic Effects of Catecholamines	220
6.2.4.3. Role of Brown Adipose Tissue in Nonshivering Thermogenesis	221
6.2.5. Substrate Mobilization	224
6.2.5.1. Lipid Metabolism	224
6.2.5.2. Carbohydrate Metabolism	225
6.2.5.3. Role of Insulin and Effects on Lipoprotein Lipase	225
6.2.6. Cardiovascular System	226
6.2.6.1. Vascular Responsiveness to NE	226
6.2.6.2. Cold Acclimation	227
6.2.7. Summary: The Role of the Sympathetic Nervous System and the Adrenal Medulla in the Mammalian Defense against Cold Exposure	227
6.3. Dietary Thermogenesis	228
6.3.1. Luxusconsumption: Adaptive Changes in Thermogenesis in Relation to Changes in Dietary Intake	228
6.3.2. Effect of Dietary Intake on Sympathoadrenal Activity	228
6.3.2.1. Suppression of Sympathetic Activity during Fasting and Caloric Restriction	228
6.3.2.2. Stimulation of Sympathetic Nervous System Activity and Thermogenesis during Feeding and Excessive Caloric Intake	230

6.3.3. CNS Assessment of Nutritional Status: The Signal That Couples Changes in Dietary Intake with Changes in Sympathetic Activity	232
6.3.3.1. Possible Role of Glucose and Insulin	233
6.3.3.2. Visceral Afferents	234
6.3.4. Summary: Adaptive Thermogenesis	234
6.4. Pheochromocytoma	235
6.4.1. Usefulness of Plasma Catecholamine Measurements in the Diagnosis of Pheochromocytoma	235
6.4.1.1. Diagnostic Considerations	235
6.4.1.2. Plasma Catecholamines	236
6.4.2. Localization of Pheochromocytoma	237
6.4.2.1. CT-Scan	237
6.4.2.2. Venous Sampling and Scintographic Localization	238
References	238

Chapter 7

Parathyroid Hormone and Calcitonin

Karen E. Kleeman and Charles R. Kleeman

7.1. Introduction	247
7.2. Chemistry, Synthesis, and Secretion	250
7.3. Control of Secretion	254
7.3.1. Control by Calcium	254
7.3.2. Control by Catecholamines	262
7.3.3. CNS Control	264
7.3.4. Vitamin D	265
7.3.5. Miscellaneous Effectors and Integrative Speculation	266
7.4. Metabolism	268
7.5. Physiology of PTH and Its Evolution	272
7.5.1. PTH and the Skeleton	275
7.5.2. PTH and the Kidney	279
7.5.2.1. Calcium Clearance	279
7.5.2.2. Phosphate Clearance	281
7.5.2.3. Glomerular Filtration	282
7.5.3. PTH and Vitamin D	283
7.6. Cellular Response to PTH	288
7.7. Hyperparathyroidism	290
7.7.1. Nature of Hyperparathyroidism	290
7.7.2. Clinical Characteristics	292
7.7.2.1. Familial Hypocalciuric Hypercalcemia	293
7.7.2.2. PTH as the "Uremic toxin"	294

7.7.3. Diagnosis	296
7.7.4. Treatment	299
7.7.5. Renal Osteodystrophy	301
7.8. Hypoparathyroidism	304
7.8.1. Presentation and Diagnosis	304
7.8.2. Pseudohypoparathyroidism	306
7.8.3. Treatment	308
7.9. Calcitonin	309
7.9.1. Origins, Embryology, Structure, and Metabolism	310
7.9.2. Assay	311
7.9.3. Secretion and Its Control	311
7.9.4. Does Calcitonin Have a Physiologic Role in Man?	313
7.9.5. Calcitonin as a Tumor Marker	316
7.9.6. Therapeutic Uses of Calcitonin	317
7.9.6.1. Paget's Disease	317
7.9.6.2. Hypercalcemia	317
7.9.6.3. Osteoporosis	318
References	318

Chapter 8

Ectopic Hormone Syndromes

Louis M. Sherwood

8.1. Etiology and Mechanisms of Ectopic Hormone Production ..	345
8.2. Recent Developments in Specific Hormone Syndromes	351
8.2.1. Ectopic Production of Corticotropin	351
8.2.2. Ectopic Production of Lipotropin	355
8.2.3. Ectopic Production of GH and GHRH	358
8.2.4. Ectopic Production of Gonadotropin	359
8.2.5. Ectopic Production of Thyrotropin	363
8.2.6. Ectopic Production of Vasopressin	364
8.2.7. Ectopic Production of Nonsuppressible Insulin-like Activity	367
8.2.8. Ectopic Production of Calcium-Mobilizing Substances	369
8.2.9. Ectopic Production of Calcitonin	373
8.2.10. Metabolic Bone Diseases Associated with Tumors ..	377
8.2.11. Ectopic Production of Tumors Associated with Diarrhea	379
8.2.11.1. Gastrointestinal Hormones	379
8.2.11.2. Glucagon-Producing Tumors	381
8.2.11.3. Somatostatin-Producing Tumors	383
8.2.12. Disorders Due to Ectopic Erythropoietin Production	386

8.2.13. Ectopic Production of Renin	386
8.2.14. Ectopic Production of Other Proteins by Tumors ...	387
References	387

Chapter 9

Vasopressin

Gary R. Robertson

9.1. Introduction	403
9.2. Anatomy	404
9.3. Biosynthesis	405
9.4. Secretion	406
9.4.1. Osmoregulation	406
9.4.2. Baroregulation	410
9.4.3. Nociceptive Influences	412
9.4.4. Emetic Influences	412
9.4.5. Glucopenic Stimuli	413
9.4.6. Hypoxic Stimuli	413
9.4.7. Pharmacological Influences	414
9.4.7.1. Opiates	414
9.4.7.2. Nicotine	417
9.4.7.3. Other Drugs with Antidiuretic Effects	418
9.4.7.4. Drugs with Diuretic Effects	419
9.4.7.5. Miscellaneous	419
9.5. Biological Actions	420
9.5.1. Renal	420
9.5.1.1. cAMP	421
9.5.1.2. Prostaglandins	421
9.5.1.3. Kinins and Kallikreins	422
9.5.1.4. Calcium and Calmodulin	422
9.5.1.5. Somatostatin	423
9.5.1.6. Vasopressin Antagonists	423
9.5.1.7. Other Factors	423
9.5.2. Vascular	424
9.5.3. Extrarenal, Extravascular	425
9.6. Pathology	426
9.6.1. Deficient Secretion	426
9.6.1.1. Neurohypophyseal Damage	426
9.6.1.2. Osmoreceptor Damage	427
9.6.2. Deficient Renal Response	428
9.6.3. Excessive Secretion	429
9.6.3.1. Inappropriate Antidiuresis	429

CONTENTS	xv
9.6.3.2. Adrenal Insufficiency	431
9.6.3.3. Edema-Forming States	432
9.6.3.4. Diabetes Mellitus	432
9.6.3.5. Hypertension	433
References	434
 Index	 451